We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Cambridge Cognition Holdings Plc | COG | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 34.50 | 08:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 34.50 | 34.50 | 34.50 | 34.50 |
| Industry Sector |
|---|
| HEALTH CARE EQUIPMENT & SERVICES |
| Top Posts |
|---|
Posted at 12/9/2024 16:04 by jasperlachat Beat me to it earwacks! Cog is in commercial mode now, thanks Storky but a replacement driver required. |
Posted at 05/9/2024 13:33 by 40 fathoms This was posted today, no RNS but interesting nonetheless.Don't seem able to post the link, so here is a copy of the text "US patient recruitment firm Splash Clinical has teamed up with UK-based digital brain health services provider Cambridge Cognition (COG) to help sponsors find people to participate in central nervous system (CNS)-focused drug trials. The new partnership – financial terms of which were not disclosed – will see Splash utilize COG’s pre-screening technology to assess potential participants for studies focusing on CNS indications. In a press statement, Splash CEO Matt Teuteberg, said, “By integrating their assessment tools into our platform, we will increase our efficiency in finding the right patients for clinical trials. This partnership will save time and resources for our clients and ultimately make treatments available for patients faster.” CNS recruitment Finding the right patients to take part in drug research is always difficult, nonetheless of the disease involved. Recruiting for trials focusing on neurological disorders is a particular challenge. For example, a 2023 study in the journal Innovations in Clinical Neuroscience suggested the lack of information about CNS patients combined with the nature of the diseases themselves are the issue. “In contrast to other therapeutic areas, such as oncology or cardiovascular diseases, there are no large clinical research networks for CNS, making it more difficult to efficiently reach patients in their care setting. There are also challenges associated with CNS disorders themselves that are not relevant to other therapeutic areas … Thus, the timely recruitment and retention of the right and representative patients is a challenge for CNS clinical trials.” COG’s technology is designed to address such difficulties. The system consists of an online cognitive assessment portal that gathers and processes data from potential study participants. According to the firm, the assessment, which takes around ten minutes, reduces screening failures and increases the quality of patients entering the trial. Splash said that, in combination with its own suite or recruitment tools, the new tech will help it reach a broader population while maintaining high-quality standards. Liam Kaufman, Cambridge Cognition’s vice president of clinical sciences, emphasized the potential benefits of the collaboration, explaining “They’ve got a great recruitment platform and a solid track record in recruitment. Our tools complement their process perfectly. Our goal is to make it easier for researchers to find the right participants for their CNS trials. It’s a win-win for everyone involved.” She added that during a pilot collaboration completed last year, COG’s software helped filter in hard-to-find patients with early Alzheimer’s symptoms. News of the collaboration comes a few months after the Michael J. Fox Foundation began using COG’s technology to identify the cognitive profile of Parkinson’s Disease patients as part of an effort to identify biomarkers – and potential druggable targets – for the condition. |
Posted at 31/8/2024 10:25 by earwacks I remember a few years back a director of an aim company telling me his solicitor advised reporting as a little to the market as possible and preferably nothing at all. Some seem to have turned this in to an absolute art form, others seem to court the market too much. You only have to look at the top holders list in COG to see they are not too bothered with investor relations with PIs. I seem to remember Vox markets or Paul Scot saying they hoped to do an interview with Cog. Presumably too busy or not keen. It does seem that private investor’s frequent trades can mess with the share price on very low volumes. I guess this can become an issue with small companies when trying to raise finance |
Posted at 25/8/2024 09:12 by greyingsurfer Most public sector workers have seen real terms pay cuts over the past 14 years, while private sector workers have generally kept up with inflation overall. It was inevitable that some catching up had to happen. The costs of strikes, inability to keep essential skilled people like nurses, considerably out weigh the costs of failing to act. (Not sure what this, or the post I'm responding to has to do with COG though?) |
Posted at 24/8/2024 18:57 by horseyphil 'Brighter Tomorrow' if you are in the public sector...until other people's money runs out! We're on a downward trajectory as Labour pays back the unions. But it's the total incompetence of the Tory governments from 2010-24 that's brought all this on.Ironic that GBP is showing such strength, belies the economic realities and, at some point, will be a great short. The UK economic future is dire, imho. Fortunately, most of our better companies earn the majority of their revenues abroad, COG included I imagine. |
Posted at 22/8/2024 09:51 by bmcollins The one thing I am uncomfortable with is a large part of their cost cutting was over 35% off of R&D.To me R&D is the very lifeblood to a company like COG, could this mean that they will stop being as innovative as they have been or were they just wasting previous years expenditure on it ? I fear the answer could be the former, but as I am very far from being a scientist I'll leave that for others to conclude. |
Posted at 23/7/2024 12:41 by jasperlachat Wishful thinking perhaps but I think we will start to see a flow of contracts now that Cog has strengthened its balance sheet and evidenced its shareholder support. |
Posted at 25/6/2024 09:37 by yump 40FThanks for that and your history of informative posts - I’ve read a lot of them ! A few at 3-4mln on top of a regular run of the 2mln ones would certainly jump the profits, given the apparent gearing. If there is a good time to buy then now seems pretty good. I’d seen COG before but I’m ultra cautious with anything medical (there seems to be almost inevitable hype with anything new) as have been caught a couple of times in stocks going nowhere, although to be fair they were both dependent on selling into the NHS. I’ve got a few HVO which at least like COG is selling to commercial customers who are also trying to make profits. |
Posted at 25/6/2024 01:04 by 40 fathoms @bedford1976 - They are already international in their reach and the significant percentage of their revenue is generated outside of the UK. This is mainly done directly and not via partnership. That said they do have an exclusive partnership for the China market and they have talked in the past about the possibility of non exclusive partnerships with CROs and certain Pharma. This aside I think most likely partnerships are likely to be technology based rather than geographical. The recent ActiGraph partnership being a good example. The other areas they have suggested they would look to partnership is for the healthcare and diagnostics opportunity.@Yump - For the potential size and scope of larger contracts you can look at Cogstate listed in Australia. They have a contracted order book in excess of US$100 million and in the last 3 or 4 years they have signed 1 contract in excess of US$10 million and one in excess of US$ 25 million. The larger one was for Eli Lilly and they worked on the Donanamab Phase III trial, which are currently with the FDA for approval. Both of these contracts were for providing work in to Phase III AD trials (AD is Cogstate's core area. About half of these amounts is accounted for by the provision of raters and rater training, which COG does not provide, so these numbers would need to be cut by 50% to get a sense of what a very large contract for COG might look like. In the next 24/36 months it is a certainty that we will see numerous contracts in excess of GBP 3 million and maybe one or two that tops GBP 5 million. |
Posted at 23/4/2024 07:27 by 40 fathoms Today's RNS confirms the Cambridge Cognitions equity in Monument Therapeutics is valued at @2 million based on the closed funding round. This compares to a carrying value of GBP65k. In addition the 12.5% royalty is worth considerably more than the equity. So at the mark from this recent funding round the value of Monument Therapeutics to Cambridge Cognition is in excess of 5 million. Should this or Monument's other drug enter phase II trials the total value will be significantly more than the current COG market cap.Monument Therapeutics strategy is out-license Phase II drug development. So its possible, with a favorable outcome in this proof of mechanism trial, that in the next 12 months a deal could be reached with Pharma. It is probably worth pointing out that Monument Therapeutics is not developing new drugs, its reformulating generic drugs and paring them with a digital biomarker to ensure they get to patients in which they will work. This should remove safety related risk from the clinical trials as these well known and widely used APIs. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
